BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

Madrigal Pharmaceuticals reported Q3 revenue of $431.3M, up 50%, with Rezdiffra sales exceeding $1.1B YTD. Earnings were $1.83 per share, beating estimates. Analysts raised price targets to $743 (Truist) and another increase (Canaccord). Retail sentiment remains bullish despite a 32% stock decline in 2026.

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

Madrigal Pharmaceuticals (MDGL) reported real-world study results for Rezdiffra at AASLD. Up to 93% of patients showed liver stiffness improvement, 72% remained on treatment for a year, and safety findings aligned with trials. Improvements were seen across diverse patient groups, including those using GLP-1 therapies.

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, with CEO William Sibold highlighting rapid growth of Rezdiffra and market expansion. The company anticipates late 2027 readout for MAESTRO-NASH and plans a 2,000+ patient MAESTRO-CSPH study.

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.

Citi raised its price target for Madrigal Pharmaceuticals (MDGL) to $760, citing strong quarterly results and favorable trial timelines, representing a 76% upside. Despite a 31% YTD drop, retail sentiment on StockTwits shifted to 'extremely bullish'.